RxDoctor Payments Data

Ravinder Gandhi, MD

Pulmonary Disease · Wyandotte, MINPI 1003995689

Payments from drug & device makers

$5,140in general payments, 2019–2025

Across 241 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$501
  • GSK$489
  • Harmony Biosciences LLC$447
  • Regeneron Healthcare Solutions, Inc.$385
  • AstraZeneca$367
  • UCB, Inc.$284
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$4,71692%
  • Education$4248%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,140 in reported general payments places this provider in the 65th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$558,308
Medicare patients
557
Services billed
5,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate29$376,862
Trelegy ElliptaFluticasone/Umeclidin/Vilanter396$331,824
Dupixent PenDupilumab58$232,775
Breztri AerosphereBudesonide/Glycopyr/Formoterol161$112,441
Breo ElliptaFluticasone/Vilanterol137$64,372
Spiriva RespimatTiotropium Bromide74$56,973
Dupixent SyringeDupilumab13$48,202
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr72$47,458
NucalaMepolizumab12$36,133
Stiolto RespimatTiotropium Br/Olodaterol Hcl54$31,849
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate69$21,701
Incruse ElliptaUmeclidinium Bromide53$21,114
SymbicortBudesonide/Formoterol Fumarate43$14,659
Ventolin HfaAlbuterol Sulfate190$11,874
Albuterol Sulfate HfaAlbuterol Sulfate301$11,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta$489$500,901670 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$93$465,685157 claims
AstraZenecaBreztri Aerosphere, Symbicort$367$127,100204 claims
PfizerEliquis$16$6,26211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Wyandotte

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →